Back to top
more

Inari Medical (NARI)

(Delayed Data from NSDQ)

$57.98 USD

57.98
972,472

+3.18 (5.80%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $58.68 +0.70 (1.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (155 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Retain Align Technology (ALGN) Stock Now

Investors are optimistic about Align Technology (ALGN), led by its strong global presence.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Fall

Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3

Myriad Genetics' (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.

Insulet (PODD) Q3 Earnings Beat, 2023 Sales Growth View Up

Insulet's (PODD) third-quarter 2023 revenues increase year over year as a result of continued high demand for Omnipod 5.

Inari Medical, Inc. (NARI) Loses -27.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Inari Medical, Inc. (NARI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates

Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.

Teleflex (TFX) Q3 Earnings Top Estimates, 2023 Outlook Up

Teleflex's (TFX) year-over-year revenue growth was driven by all global product categories in Q3.

Haemonetics (HAE) Q2 Earnings Top Estimates, 2024 View Up

The robust volume growth and price benefits in the Plasma business driven by strong momentum in U.S. collections and price benefit Haemonetics' (HAE) fiscal second-quarter results.

Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase

Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.

Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises

Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.

Envista (NVST) Q3 Earnings Miss Estimates, Gross Margin Down

Envista's (NVST) Q3 performance is impacted by the negative impact of Russia and the weakness of higher-end specialty procedures in developed markets.

CVS Health (CVS) Q3 Earnings Surpass Estimates, Margins Up

Robust sales growth across all three operating segments drove CVS Health's (CVS) third-quarter results.

IDEXX (IDXX) Q3 Earnings Top Estimates, '23 Sales View Down

IDEXX (IDXX) delivers better-than-expected earnings in the third quarter of 2023.

QIAGEN (QGEN) Q3 Earnings and Revenues Beat, Margins Down

In an increasingly challenging macro environment, QIAGEN (QGEN) surpasses the earnings and revenue outlook in the third quarter of 2023.

Indrajit Bandyopadhyay headshot

Medical Device Stocks to Watch for Earnings on Nov 1: MCK & More

Medical Device companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, QDEL, GKOS and NARI are placed ahead of their earnings release.

Zacks Industry Outlook Highlights Alcon, STERIS and Inari Medical

Alcon, STERIS and Inari Medical are part of the Zacks Industry Outlook article.

Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View

The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.

Urmimala Biswas headshot

3 Medical Instruments Stocks Countering Industry-Wide Headwinds

The Zacks Medical - Instruments industry is being affected by ongoing inflation and a tightening monetary policy. However, the rising demand for digital health offers some respite. ALC, STE and NARI are poised to brave the challenges.

Chemed (CHE) Q3 Earnings and Revenues Surpass, Margins Rise

Chemed's (CHE) third-quarter 2023 performance reflects strength in the VITAS segment.

ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Down

ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust growth in the mask product portfolio.

Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter.

Edwards Lifesciences (EW) Q3 Earnings Match Mark, Margins Dip

Edwards Lifesciences (EW) TMTT performance benefits from the accelerated adoption of the differentiated PASCAL precision platform in the third quarter.

Labcorp (LH) Q3 Earnings and Revenues Beat, Margins Fall

Labcorp (LH) delivers a strong performance in the third quarter of 2023 across the Diagnostics Laboratories and Biopharma Laboratory Services businesses.

Integra's (IART) Q3 Earnings Miss Estimates, 2023 View Cut

The impact of lost revenues and an increase in the return provision related to the Boston product recall dent Integra's (IART) Q3 revenues.

Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q3 performance.